title: Successful combination of anti-CD33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia.
authors.forename: Mathias
authors.initials: M
authors.lastname: Hänel
authors.forename: Christian
authors.initials: C
authors.lastname: Thiede
authors.forename: Anett
authors.initials: A
authors.lastname: Helwig
authors.forename: Gabriele
authors.initials: G
authors.lastname: Prange-Krex
authors.forename: Jana
authors.initials: J
authors.lastname: Babatz
authors.forename: Michael
authors.initials: M
authors.lastname: Haack
authors.forename: Frank
authors.initials: F
authors.lastname: Kroschinsky
authors.forename: Sebastian
authors.initials: S
authors.lastname: Fetscher
authors.forename: Gerhard
authors.initials: G
authors.lastname: Ehninger
authors.forename: Martin
authors.initials: M
authors.lastname: Bornhäuser
mesh_terms: D000208:Acute Disease; D000328:Adult; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D000079982:Gemtuzumab; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000601:surgery; D012086:Reoperation; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab